Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
American Journal of Medical Genetics. Part A|May 17, 2007
Chromosomal microarray analysis (CMA) detects a large X chromosome deletion including FMR1, FMR2, and IDS in a female patient with mental retardationFrank J Probst, Elizabeth R Roeder, Victoria B Enciso, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 17, 2009
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)Matthew J Fell, Kenneth W Perry, Julie F Falcone, et al.
The International Journal of Neuropsychopharmacology|June 24, 2010
Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in ratsJorn Arnt, Benny Bang-Andersen, Ben Grayson, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT(1A) receptor antagonism/SSRI activities. Part 2Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, et al.
Neurobiology of Disease|February 15, 2011
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndromeJosien Levenga, Shigemi Hayashi, Femke M S de Vrij, et al.
EMBO Molecular Medicine|February 22, 2022
Intercepting IRE1 kinase-FMRP signaling prevents atherosclerosis progressionZehra Yildirim, Sabyasachi Baboo, Syed M Hamid, et al.
Blood|August 16, 2011
Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligandAshish Jain, Joseph A Kovacs, David L Nelson, et al.
Annals of Neurology|June 18, 2019
Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishmentsSteven U Walkley, Leonard Abbeduto, Mark L Batshaw, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2005
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapineKurt Rasmussen, Mark J Benvenga, Frank P Bymaster, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2022
Identification of PSMB5 as a genetic modifier of fragile X-associated tremor/ataxia syndromeHa Eun Kong, Junghwa Lim, Alexander Linsalata, et al.
Pageof 15